Rothia mucilaginosa:慢性肺病患者呼吸道中的抗炎细菌
研究探讨肺微生物群中Rothia mucilaginosa的免疫调节作用。体外三维细胞培养和小鼠模型显示,该菌抑制病原体或脂多糖诱导的促炎反应;在支气管扩张成人队列中,Rothia丰度与痰中IL-8、IL-1β及MMP-1、MMP-8、MMP-9呈负相关。机制上,该菌通过减少IκBα磷酸化抑制NF-κB通路活化。
要点
- R. mucilaginosa可抑制病原体或LPS诱导的促炎反应
- 支气管扩张患者痰中Rothia丰度与促炎标志物负相关
- 该菌通过抑制NF-κB通路发挥抗炎作用
核心结论
- 下呼吸道中R. mucilaginosa的存在可能减轻炎症,进而影响慢性呼吸系统疾病的严重程度和进展。
研究设计与样本
- 体外三维细胞培养模型和小鼠模型评估R. mucilaginosa的免疫调节作用。
- 在支气管扩张成人队列中分析Rothia丰度与痰促炎标志物的相关性。
主要发现
- R. mucilaginosa对病原体或脂多糖诱导的促炎反应具有抑制作用。
- 支气管扩张成人队列中,Rothia丰度与痰中IL-8、IL-1β、MMP-1、MMP-8、MMP-9呈负相关。
- 机制上,R. mucilaginosa通过减少IκBα磷酸化抑制NF-κB通路激活。
临床怎么用
- 提示下呼吸道R. mucilaginosa丰度可能作为炎症调节的生物标志物。
- 为慢性气道炎症疾病提供潜在抗炎微生物干预思路。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic airway inflammation is the main driver of pathogenesis in respiratory diseases such as severe asthma, chronic obstructive pulmonary disease, cystic fibrosis (CF) and bronchiectasis. While the role of common pathogens in airway inflammation is widely recognised, the influence of other microbiota members is still poorly understood. METHODS: We hypothesised that the lung microbiota contains bacteria with immunomodulatory activity which modulate net levels of immune activation by key respiratory pathogens. Therefore, we assessed the immunomodulatory effect of several members of the lung microbiota frequently reported as present in CF lower respiratory tract samples. RESULTS: We show that Rothia mucilaginosa, a common resident of the oral cavity that is also often detectable in the lower airways in chronic disease, has an inhibitory effect on pathogen- or lipopolysaccharide-induced pro-inflammatory responses, in vitro (three-dimensional cell culture model) and in vivo (mouse model). Furthermore, in a cohort of adults with bronchiectasis, the abundance of Rothia species was negatively correlated with pro-inflammatory markers (interleukin (IL)-8 and IL-1β) and matrix metalloproteinase (MMP)-1, MMP-8 and MMP-9 in sputum. Mechanistic studies revealed that R. mucilaginosa inhibits NF-κB pathway activation by reducing the phosphorylation of IκBα and consequently the expression of NF-κB target genes. CONCLUSIONS: These findings indicate that the presence of R. mucilaginosa in the lower airways potentially mitigates inflammation, which could in turn influence the severity and progression of chronic respiratory disorders.
引用
- Rigauts C, Aizawa J, Taylor SL, et al. R othia mucilaginosa is an anti-inflammatory bacterium in the respiratory tract of patients with chronic lung disease. Eur Respir J. 2022. PMID: 34588194. doi:10.1183/13993003.01293-2021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。